Argenx SE (NASDAQ:ARGX) is one of the best NASDAQ stocks to buy according to hedge funds. On February 26, Argenx reported earnings for 2025, achieving its first year of annual operating profitability ...

(ENXTBR:ARGX) reported positive topline data from its Phase 3 ADAPT OCULUS trial of VYVGART in ocular myasthenia gravis. The study met its primary endpoint, with statistically significant improvement ...

The Adapt Oculus trial is unique in that it includes a patient population often overlooked in clinical trials, patients ...

Positive results from Phase 3 ADAPT OCULUS study show VYVGART’s potential as the first targeted treatment for patients living with ocular MG Additional data from ADAPT SERON – the largest study of ...

A month ago, argenx announced that the FDA had accepted its application to expand Vyvgart to those with acetylcholine ...

Efgartigimod alfa–hyaluronidase significantly improves ocular symptoms in adults with ocular myasthenia gravis, according to phase 3 trial data.

Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced ...

Efgartigimod led to statistically significant improvement in key symptoms of ocular myasthenia gravis compared with placebo in a phase 3 trial.

X recently announced results from additional analyses of its blockbuster FcRn inhibitor Vyvgart in the phase III Adapt Oculus study. The study evaluated the efficacy and safety of Vyvgart administered ...

On February 26, 2026, Argenx reported positive topline Phase 3 results from its ADAPT OCULUS trial of subcutaneous VYVGART in adults with ocular myasthenia gravis, the first registrational study ...